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Abstract: Matrix metalloproteinase-9 (MMP-9) and its endogenous inhibitor, tissue inhibitor of metalloproteinase-1 
(TIMP-1), are key mediators of acute inflammation and regulators of the wound healing process. The aim of this 
systematic review was to determine the local and systemic involvement of the MMP-9/TIMP-1 system following 
burn injury. Two databases (Scopus and MEDLINE) were searched for all studies reporting MMP-9 and/or TIMP-1 
after burn injury. Based on our eligibility criteria, we reviewed 24 studies involving 508 burns patients in 11 clinical 
studies and 367 animals in 13 preclinical studies. Local, systemic, and peripheral gene expression, protein levels 
and activity of MMP-9 and TIMP-1 were assessed. Increased MMP-9 was reported at the site of injury early after 
burn trauma in all studies, and remained elevated in non-healing wounds. Increased TIMP-1 expression in burn 
wounds occurred later than MMP-9, and was persistent in hypertrophic burn scars. Similar to local expression, 
systemic MMP-9 and TIMP-1 concentrations were significantly elevated after burn injury in response to upregula-
tion of proinflammatory cytokines. While no association was found between systemic MMP-9 concentration and 
extent of injury or outcome, serum or plasma TIMP-1 showed good correlation with survival and burn severity. This 
review also found evidence of the MMP-9/TIMP-1 system contributing to secondary tissue damage distant from the 
burn site, including burn-associated musculoskeletal damage and acute lung injury. In addition, increased MMP-9 
synthesis and activity in the brain after peripheral burn may lead to blood-brain barrier dysfunction and cerebral 
edema, a significant contributor to mortality. This systematic review provides an overview of the available evidence 
of the role of MMP-9 and TIMP-1 in burn injury pathophysiology and finds that TIMP-1 may be a promising biomarker 
in outcome prognostication of burns patients. Large-scale studies of both pediatric and adult burns patients with 
increased female representation and repeated sampling are recommended to validate the reliability of TIMP-1 as a 
prognostic marker following burn injury.
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Introduction
Matrix metalloproteinases (MMPs) are calcium-
dependent zinc-endopeptidases that cleave 
extracellular matrix (ECM) proteins, and there-
by play a central role in burn wound healing and 
remodeling [1-3]. Matrix metalloproteinase-9, 
or gelatinase B, has been identified as an 
important signaling protease able to modulate 
the inflammatory response and a key contribu-
tor to the wound healing process [4, 5]. 
Expression of MMP-9 is upregulated locally and 
systemically after injury in epithelial cells, endo-
thelial cells and immune cells, including mono-
cytes, macrophages, lymphocytes and dendrit-
ic cells [4, 6]. Organized wound healing and 
homeostasis is dependent on regulation of 
MMP-9 activity by its endogenous inhibitor, tis-
sue inhibitor of metalloproteinase-1 (TIMP-1) 
[7-10].
Dysregulation of the dynamic balance between 
MMP-9 and TIMP-1 leads to prolonged inflam-
mation and delayed wound healing, and might 
contribute to burn-associated secondary tissue 
damage and mortality [4, 8, 10, 11]. Burn injury 
results in upregulation of proinflammatory cyto-
kines including tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β and IL-8, which stimulate 
MMP-9 synthesis [5, 12]. In turn, MMP-9 modu-
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lates the inflammatory response by cleaving 
IL-1β and IL-8, increasing their biologic activity 
and potency [12, 13]. TIMP-1 also has a broad 
range of downstream signaling effects includ-
ing preservation of endothelial cells and plate-
lets [7]. Through these effects, MMP-9 and 
its inhibitor TIMP-1 may contribute to microvas-
cular hyperpermeability and subsequent burn-
associated edema [10]. A more thorough 
understanding of these pathophysiologic res- 
ponses is required to project patient outcomes 
and develop new therapeutic strategies. In 
response to the exponential increase in MMP-9 
research in the past few decades [4], we con-
ducted a systematic review to determine the 
role of the MMP-9/TIMP-1 system in burn inju-
ry. This review provides an overview of the avail-
able evidence in both preclinical and clinical 
studies, with recommendations for future 
research.
Materials and methods
This systematic review was conducted and is 
reported using the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines [14].
Eligibility criteria
All studies reporting MMP-9 and/or TIMP-1 
after burn injury were included. The search 
strategy included the following terms: “matrix 
metalloproteinase” or “collagenase” or “matrix 
metalloproteinase 9” or “gelatinase” or “metal-
loprotease” or “metalloendopeptidase” or “tis-
sue inhibitor of metalloproteinase” or “tissue 
inhibitor of metalloproteinase-1” and “burns” or 
“burn injury”. Studies on corneal burns and 
non-thermal burns, and studies of therapeutic 
interventions without an untreated burn injury 
group for analysis were excluded. There were 
no restrictions placed on Level of Evidence, 
study size or date of publication. Review arti-
cles, conference abstracts, and non-English 
studies were excluded from this review.
Information sources 
The literature search was conducted on publi-
cations available up to March 21, 2021. Two 
databases were searched: Scopus (1996-pres-
ent) and MEDLINE (1946-present). Reference 
lists of studies retrieved in full text were also 
hand searched to identify additional studies.
Study selection
After duplicates were removed, two investiga-
tors screened the titles and abstracts of all 
retrieved citations to identify eligible studies. 
Relevant studies were retrieved in full text 
and further reviewed by the same two investi-
gators against the inclusion criteria. The full 
text of any studies for which a definite decision 
could not be made from the title and abstract 
alone was also retrieved. Where there was dis-
agreement regarding study eligibility, a third 
investigator was consulted.
Data extraction and analysis
Two investigators extracted the necessary 
information from identified papers using a stan-
dard form developed specifically for this review. 
Data were extracted for: General characteris-
tics (authors, year, title, journal), Study charac-
teristics (study type, level of evidence, sample 
size), Subject characteristics (species, age, 
gender), Clinical characteristics (total body sur-
face area [TBSA], burn degree/depth), and 
Outcome data (parameter [MMP-9, TIMP-1], 
sample type, detection method, timepoints). 
Following data extraction, the included studies 
were too heterogeneous with regards to spe-
cies, burn severity and degree, sample type, 
detection method and time from burn injury, 
and therefore a meta-analysis was not 
conducted.
Risk of bias assessment 
Two tools were used for Risk of Bias (RoB) 
Assessment depending on study type. Animal 
studies were assessed with The Office of 
Health Assessment and Translation (OHAT) 
RoB tool developed by the National Toxicology 
Program to evaluate use of randomization, 
blinding, and outcome assessment and report-
ing. The Scottish Intercollegiate Guidelines 
Network (SIGN) checklist was used for cohort, 
case-control, and cross-sectional studies to 
assess internal validity and risk of selection, 
performance, attrition and detection bias. Each 
study was assessed as having low, moderate, 
or high risk of bias.
Results
The initial databases search produced 916 arti-
cles, leaving 761 unique articles when dupli-
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cates were removed (Figure 1). Three addition-
al articles were obtained through reference list 
searching. In total, 71 articles were examined 
in full text, after titles and abstracts were 
screened. Based on the eligibility criteria, 24 
studies were included in this systematic 
review involving 508 burns patients in 11 clini-
cal studies [5, 12, 15-23] and 367 animals in 
13 preclinical studies (Table 1). Of the preclini-
cal studies, 11 were rodent studies [3, 6, 10, 
11, 24-30] and two were porcine studies [31, 
32].
Quality and risk of bias assessment
Risk of bias (RoB) assessment showed nine low 
risk, 14 medium risk, and one medium-high 
risk study (Table 2). Five of the preclinical stud-
ies were assessed as low risk [3, 24, 26, 28, 
32] and eight were considered medium risk 
due to lack of randomization and/or blinding 
[6, 10, 11, 25, 27, 29-31]. Three of the me- 
dium risk preclinical studies did not confirm 
extent of burn injury [10, 11, 27]. Ten of the 
human studies were Level IV case-control or 
cohort studies, with one Level III cross-section-
studies included only full-thickness (FT) burns 
[6, 24-30], three covered partial thickness (PT) 
burns only [3, 31, 32], six included a mix of FT 
and PT burns [17, 18, 20-23], while one also 
incorporated superficial burns [12]. The remain-
ing six studies did not report the degree or 
depth of burn [5, 10, 11, 15, 16, 19] (Table 1). 
Of the preclinical studies, six investigated juve-
nile animals [3, 10, 24, 25, 28, 31] and five 
investigated adults [6, 11, 27, 29, 30], while 
Simonetti and colleagues compared young (7 
to 10 months) and old (19 to 28 months) rats 
[26]. The majority of the clinical studies evalu-
ated adult patients, with only pediatric patients 
in the Dasu et al. and Neely et al. patient 
cohorts [19, 21]. Only ten of the 24 studies 
reported the gender of the burn subjects (Table 
1). Male animals were exclusively used in the 
preclinical studies, with males also more preva-
lent in the clinical studies making up 58 to 77% 
of the patient cohort.
Outcome measurements
Eleven studies reported measurements of 
both MMP-9 and TIMP-1, with MMP-9 only 
Figure 1. PRISMA flow-chart. A total of 761 studies were evaluated for re-
porting of MMP-9 and/or TIMP-1 after burn injury. Titles and abstracts were 
assessed, and 71 full-text articles were eligible for evaluation. 47 articles 
were excluded, and 24 articles remained for the systematic review.
al study (Table 1). Four of the 
Level IV studies scored as low 
risk using the SIGN checklist 
(Table 2) [5, 12, 16, 17]. The 
Level III cross-sectional study 
of Nong and colleagues was 
medium risk because it was 
not blinded and the patient 
population was insufficiently 
described to assess represen-
tativeness [15]. None of the 
studies was classified as high 
risk, however the cohort study 
of Young and Grinnell had no 
control group and was medi-
um-high risk [22]. The remain-
ing five clinical studies were 
medium risk due to possible 
selection bias [18, 20], or 
because the control group was 
not well-defined [19, 21, 23] 
(Table 2).
General information of study 
population
The extent of burn injury was 
highly variable across the stud-
ies, ranging from 1 to 80% 
TBSA burns (Table 1). Eight 
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Table 1. Summary of study characteristics
Authors Year Study type Level of evidence TBSA
Degree/
Depth Burn Type Sample size Species Age
Gender 
(M/F)
Brightwell et al. [24] 2020 Animal study Foundational 
evidence
30% FT Thermal n = 13 Burn
n = 4 Control
C57BL/6-129 
mouse
Juvenile (8 weeks) NR
Hernandez et al. [11] 2018 Animal study Foundational 
evidence
40% NR Thermal 40
n = 11 Control
SD rat Adult All male
Yu et al. [3] 2017 Animal study Foundational 
evidence
NR PT Thermal 54 Nude Mouse Juvenile (6 weeks) NR
Nong et al. [15] 2016 Cross sectional study Level III >20% NR All n = 244 Burn
n = 35 Control
Human NR NR
Wiggins-Dohlvik et al. [10] 2016 Animal study Foundational 
evidence
30% NR Thermal n = 4 Burn
n = 4 Sham
SD rat Juvenile  
(5.5-9 weeks)
All male





All n = 30 TBSA>20%
n = 19 TBSA<20%
n = 6 Control
Human Adult (>18 years) 35/14
Nagy et al. [5] 2015 Retrospective cohort 
study
Level IV 15-80% NR Inhalation/Blast/
Flame/Scald
31 Human Adult (30-74 years) NR
Kubo et al. [25] 2014 Animal study Foundational 
evidence
NR FT Thermal n = 40 Burn
n = 4 Control
BALB/c mouse Juvenile (8-9 weeks) All male
Simonetti et al. [26] 2013 Animal study Foundational 
evidence
NR FT Thermal n = 24 Burn
n = 16 Control
Wistar rat Young (7-10 months)
Old (19-28 months)
All male
Stagg et al. [27] 2013 Animal study Foundational 
evidence
30% FT Thermal n = 5 Burn
n = 5 Sham
SD Rat Adult All male
Wang et al. [16] 2013 Case-control study Level IV NR NR NR 101
n = 55 Burn
Human Adult (17-97 years) 77/24
Sio et al. [28] 2010 Animal study Foundational 
evidence
30% FT Thermal 36 BALB/c mouse Juvenile (6-8 weeks) All male
Ulrich et al. [17] 2010 Case-control study Level IV >5% (21-12%) Dermal/FT NR 69
n = 19 Burn
Human Adult  
(48.2 ± 19 years)
11/8 Burn
12/39 Other
Reiss et al. [18] 2009 Cohort study Level IV 1.5-17% PT/FT NR 20 Human Pediatric & Adult  
(5-75 years)
NR
Reyes et al. [29] 2009 Animal study Foundational 
evidence
60-70% FT Thermal n = 32 Burn
n = 8 Control
SD rat Adult All male
Berger et al. [6] 2007 Animal study Foundational 
evidence
70% FT Thermal 35 SD rat Adult NR
Swann et al. [30] 2007 Animal study Foundational 
evidence
60-70% FT Thermal 72 SD rat Adult All male
Dasu et al. [19] 2003 Cohort study Level IV >40% NR NR 12 Human Pediatric
(7.9 ± 2.5 years)
NR
Ulrich et al. [20] 2003 Cohort study Level IV >5% (38-19%) PT/FT NR n = 22 Burn
n = 20 Control
Human Adult
(49.32 ± 24.2 years)
14/8 Burn
8/12 Control
Neely et al. [21] 1997 Case-control study Level IV 50% Nearly 
all FT
NR 20 Human Pediatric
(17 days-15.8 years)
NR
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Schaffer et al. [31] 1997 Animal study Foundational 
evidence
NR PT Thermal/Laser 8 Domestic pig Juvenile NR
Stricklin et al. [32] 1994 Animal study Foundational 
evidence
NR PT Thermal 4 Pig NR NR
Young & Grinnell [22] 1994 Cohort study Level IV 10-43% FT = 2
PT-FT = 1
NR 3 Human Adult (42-56 years) 2/1
Stricklin et al. [23] 1993 Cohort study Level IV 1-76% PT/FT Thermal/
Electricity
n = 33 Burn
n = 3 Control
Human Pediatric & Adult  
(1-72 years)
24/7
NR = Not Reported; TBSA = total body surface area; S = superficial; PT = partial thickness; FT = full thickness; SD = Sprague-Dawley; M = male; F = female.
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reported in a further 11 studies (Table 3). The 
two studies of Stricklin and colleagues mea-
sured the inhibitor alone in porcine and human 
skin [23, 32]. The levels of MMP-9 and TIMP-1 
were measured in burned skin samples in 
seven studies [3, 17, 18, 21, 25, 26, 31], while 
Hastbacka et al., Reiss et al., and Young and 
Grinnell analyzed burn blister fluids [12, 18, 
22]. Circulating levels of MMP-9 and TIMP-1 in 
serum or plasma were measured in ten studies 
[5, 12, 15, 17, 19, 20, 22, 27, 28, 30] (Table 3). 
MMP-9 expression was analyzed in lung tissue 
by Wiggins-Dohlvik and colleagues [10], in 
Achilles tendon by Hernandez and colleagues 
[11], and in skeletal muscle by Brightwell and 
group [24], who also reported TIMP-1 expres-
sion. Brain expression of MMP-9 was a primary 
outcome for one case-control study [16] and 
three rat studies [6, 29, 30]. Measurements 
were taken at multiple time-points in 17 out of 
24 studies ranging from 30 minutes after injury 
to 6 months post-burn (Table 3). Outcome mea-
sures were (i) mRNA (gene expression) using 
microarray analysis, quantitative reverse tran-
scriptase polymerase chain reaction (RT-qPCR), 
or in situ hybridization (ISH); (ii) protein mea-
sured using immunohistochemistry (IHC), west-
ern blot (WB), or enzyme linked immunosorbent 
assay (ELISA); or (iii) MMP-9 activity using gela-
tin zymography or Sensolyte assay.
Local expression and activity of MMP-9 and 
TIMP-1 after burn injury
Nine studies included in this systematic review 
reported local gene expression or protein levels 
of MMP-9 in burned skin samples [3, 17, 18, 
21, 25, 26, 31] and/or blister fluids [12, 18, 22] 
(Table 4). All studies reported significant 
increases in MMP-9 mRNA or protein compared 
to unburned controls, except Ulrich et al. who 
showed no difference more than four months 
post-injury [17]. MMP-9 was detectable in blis-
ter fluids on the day of injury [12, 22], with sig-
nificantly elevated levels in skin and blisters 
ranging from 6 hours to 15 days post-burn 
depending on the study [3, 21, 22, 25, 31]. 
Increased MMP-9 was reported in both pediat-
ric and adult animals and patients, however 
Simonetti and colleagues demonstrated signifi-
cantly higher MMP-9-positive epithelial cells in 
wounded old skin compared with wounded 
Table 2. Risk assessment
Authors Year Study type RoB tool
Risk 
assessment Details
Brightwell et al. [24] 2020 Animal study OHAT Low
Hernandez et al. [11] 2018 Animal study OHAT Medium No blinding; No confirmation of injury
Yu et al. [3] 2017 Animal study OHAT Low
Nong et al. [15] 2016 Cross-sectional study SIGN Medium No blinding; No population details 
Wiggins-Dohlvik et al. [10] 2016 Animal study OHAT Medium No randomization, blinding, or confirmation of injury 
Hastbacka et al. [12] 2015 Cohort study SIGN Low 
Nagy et al. [5] 2015 Cohort study SIGN Low
Kubo et al. [25] 2014 Animal study OHAT Medium No randomization or blinding
Simonetti et al. [26] 2013 Animal study OHAT Low
Stagg et al. [27] 2013 Animal study OHAT Medium No randomization; No confirmation of injury
Wang et al. [16] 2013 Case-control study SIGN Low
Sio et al. [28] 2010 Animal study OHAT Low
Ulrich et al. [17] 2010 Case-control study SIGN Low
Reiss et al. [18] 2009 Cohort study SIGN Medium No blinding; Possible selection bias
Reyes et al. [29] 2009 Animal study OHAT Medium No randomization or blinding 
Berger et al. [6] 2007 Animal study OHAT Medium No randomization or blinding 
Swann et al. [30] 2007 Animal study OHAT Medium No randomization or blinding 
Dasu et al. [19] 2003 Cohort study SIGN Medium Control not well defined
Ulrich et al. [20] 2003 Cohort study SIGN Medium Possible selection bias
Neely et al. [21] 1997 Case-control study SIGN Medium Control not well identified
Schaffer et al. [31] 1997 Animal study OHAT Medium No randomization or blinding 
Stricklin et al. [32] 1994 Animal study OHAT Low
Young & Grinnell [22] 1994 Cohort study SIGN Medium-High No control
Stricklin et al. [23] 1993 Cohort study SIGN Medium Control not well defined
RoB = risk of bias; OHAT = Office of Health Assessment and Translation; SIGN = The Scottish Intercollegiate Guidelines Network.
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young skin in a rat model (60.6 ± 2.5% vs 30.0 
± 3.2%; P<0.0001) [26].
With regards to MMP-9 enzyme activity, Neely 
et al. reported a significant 20 to 30-fold 
increase in burned skin from pediatric patients 
when compared with unburned skin [21]. 
MMP-9 activity assays of blister fluids from 
human patients with both partial and full-thick-
ness burns conducted by Reiss et al. [18] and 
Young and Grinnell [22] showed differences 
related to the severity of injury, and between 
non-healing wounds and healing or epithelializ-
ing wounds (Table 4). MMP-9 activity was 
increased in full-thickness and non-healing 
burns, whereas active MMP-9 was reduced or 
absent from less severe and healed wounds 
[18, 22].
TIMP-1 expression at the site of injury incre- 
ased later than MMP-9 in both animals and 
humans, with weak or irregularly distributed 
TIMP-1 on days 2 to 3 post-burn [3, 23] before 
significant increases from about day 5 to 14 [3, 
21, 32]. Schaffer et al. [31] and Stricklin et al. 
[23] both reported a decrease in skin TIMP-1 
levels as burn wound repair progressed (Table 
4). TIMP-1 expression at a later stage of wound 
healing (>4 months post-burn) was shown by 
Ulrich and colleagues [17] to be significantly 
increased in extended hypertrophic burn scars. 
Analysis of burn blister fluids showed detect-
Table 3. Study samples, measurements and timepoints
Authors Year Parameter Sample Timepoints Detection Method
Brightwell et al. [24] 2020 MMP-9 + TIMP-1 Skeletal muscle 7, 14, 21 days Protein (WB)
Hernandez et al. [11] 2018 MMP-9 Tendon 1, 3, 7, 14 days Protein (WB)
Yu et al. [3] 2017 MMP-9 + TIMP-1 Skin 2, 4, 6, 8 weeks Protein (IHC)
Nong et al. [15] 2016 MMP-9 + TIMP-1 Serum Within 96 hours after injury Gene expression (Microarray 
analysis)
Wiggins-Dohlvik et al. [10] 2016 MMP-9 Lung 3 hours after injury Protein (WB)
Activity (Sensolyte assay)
Hastbacka et al. [12] 2015 MMP-9 + TIMP-1 Blister fluid + plasma On admission; every 3 hours to 24 
hours; day 1, 2, 3, 7, 14, 21
Protein (ELISA)
Nagy et al. [5] 2015 MMP-9 + TIMP-1 Plasma From admission to day 6 Protein (ELISA)
Kubo et al. [25] 2014 MMP-9 Skin 3, 6, 9, 12 hours; day 1, 2, 3, 5, 
7, 14 
Protein (IHC)
Simonetti et al. [26] 2013 MMP-9 Skin 7, 14, 21 days Protein (IHC) 
Stagg et al. [27] 2013 MMP-9 Serum 3 hours after injury Protein (WB)
Activity (zymography)
Wang et al. [16] 2013 MMP-9 Brain Within 48 hours post-mortem (21 
hours median)
Gene expression (RT-qPCR)
Sio et al. [28] 2010 MMP-9 Plasma 8 hours after injury Protein (ELISA + WB + IHC)
Ulrich et al. [17] 2010 MMP-9 + TIMP-1 Skin + serum >4 months after injury Gene expression (RT-qPCR)
Protein (ELISA)
Reiss et al. [18] 2009 MMP-9 + TIMP-1 Blister fluid + skin 5-32 days after injury Protein (WB)
Activity (zymography)
Reyes et al. [29] 2009 MMP-9 Brain 3, 7, 24 hours after injury Protein (WB)
Berger et al. [6] 2007 MMP-9 Brain 3, 7 hours after injury Gene expression (RT-qPCR)
Swann et al. [30] 2007 MMP-9 Brain + serum 7, 24, 72 hours after injury Gene expression (RT-qPCR)
Protein (ELISA)
Activity (zymography)
Dasu et al. [19] 2003 MMP-9 + TIMP-1 Serum 30 min; 3, 7, 21 days Protein (ELISA)
Ulrich et al. [20] 2003 MMP-9 + TIMP-1 Serum Within 2 hours of injury; 1, 3, 7, 14 
days; 1, 3, 6 months
Protein (ELISA)
Neely et al. [21] 1997 MMP-9 + TIMP-1 Skin 3-5 days after injury Gene expression (RT-qPCR) 
Activity (zymography)
Schaffer et al. [31] 1997 MMP-9 + TIMP-1 Skin 5, 10, 15 days after injury Gene expression (ISH)
Stricklin et al. [32] 1994 TIMP-1 Skin 6 days after injury Gene expression (ISH)
Young & Grinnell [22] 1994 MMP-9 Blister fluid + plasma 4-8 hours after injury; then every 
48-72 hours until day 8-13
Protein (IHC)
Activity (zymography)
Stricklin et al. [23] 1993 TIMP-1 Skin 2-34 days after injury Gene expression (ISH)
MMP-9 = matrix metalloproteinase-9;TIMP-1 = tissue inhibitor of metalloproteinase-1; WB = Western blot; IHC = immunohistochemistry; ELISA = enzyme-linked immuno-
sorbent assay; RT-qPCR = quantitative reverse transcriptase polymerase chain reaction; ISH = in situ hybridization.
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able levels of TIMP-1 protein on hospital admis-
sion in the Hastbacka et al. study [12], which 
contrasted with Reiss et al.’s findings of TIMP-1 
in only one of 20 patients in samples collected 
5 to 32 days after injury [18].
Systemic expression of MMP-9 and TIMP-1 
after burn injury
Early increases in circulating levels of MMP-9 
on the day of burn injury were reported by 
Hastbacka et al. [12], Nagy et al. [5], and Stagg 
et al. [27] (Table 5). The temporal expression 
and/or activity of serum or plasma MMP-9 dif-
fered across studies with Swann et al. [30] and 
Hastbacka et al. [12] showing a fall to control 
levels by 7 to 12 hours and 12 to 24 hours 
respectively. Nagy et al. [5] also reported 
decreasing levels after admission, including 
significantly lower MMP-9 on day 4 to 6 com-
pared to unburned controls. In contrast, Ulrich 
and colleagues showed increased serum 
MMP-9 between day 3 and 14 post-burn [20], 
while systemic MMP-9 remained unchanged in 
a study of pediatric burn patients until day 21 
[19].
All studies that reported circulating levels of 
TIMP-1 showed significant increases compared 
to pre-burn levels and/or unburned controls [5, 
12, 15, 17, 19, 20] (Table 5). Increases were 
reported as early as day 1 post-burn, with high-
er levels maintained up to 6 months after injury 
[20]. Similar to findings in skin samples, serum 
TIMP-1 >4 months post-burn was significantly 
increased in patients with extended hypertro-
phic burn scars [17]. Hastbacka et al. reported 
significantly higher plasma levels of TIMP-1 in 
patients with >20% TBSA burns compared with 
burns covering <20% TBSA (P<0.002) [12] 
(Table 5).
Peripheral expression and activity of MMP-9 
and TIMP-1 after burn injury
Two rodent studies investigated MMP-9 and 
TIMP-1 expression in the musculoskeletal sys-
tem after 30-40% TBSA burn injury [11, 24] 
(Table 6). Brightwell et al. showed no change in 
MMP-9 levels in skeletal muscle dorsal to the 
burn site, but significantly increased TIMP-1 on 
days 7 and 14 post-burn [24]. In contrast, 
Hernandez and colleagues reported two signifi-
cant increases in MMP-9 in Achilles tendon 
after burn; the first on day 3, followed by a >20-
fold increase on day 14 [11]. In another rodent 
study, Wiggins-Dohlvik et al. found a non-signif-
icant elevation in MMP-9 protein together with 
a significant 40% increase in MMP-9 activity 
Table 4. Local expression and activity of MMP-9 and TIMP-1 following burn injury
Authors Year Parameter Major Findings 
Yu et al. [3] 2017 MMP-9 + TIMP-1 ● MMP-9 low on day 3, from day 7 to day 14 (P<0.05 vs control)
● TIMP-1 irregularly distributed on day 3, from day 10 to 14 (P<0.001 vs control)
Hastbacka et al. [12] 2015 MMP-9 + TIMP-1 ● MMP-9 (53.6 ng/ml) and TIMP-1 (81.7 ng/ml) detectable in burn blister fluids on burn center 
admission
Kubo et al. [25] 2014 MMP-9 ● MMP-9 significantly from 6 hours to 14 days post-injury
Simonetti et al. [26] 2013 MMP-9 ● MMP-9 in wounded skin vs unwounded skin in both young and old animals (P<0.0001)
Ulrich et al. [17] 2010 MMP-9 + TIMP-1 ● No difference in MMP-9 expression in burn scar tissue vs controls
● TIMP-1 in hypertrophic scars after burn (P<0.05)
Reiss et al. [18] 2009 MMP-9 + TIMP-1 ● MMP-9 in injured tissue; not expressed in uninjured skin
● Active MMP-9 high in full-thickness and non-healing wounds
● Inactive MMP-9 higher in less severe and healed wounds
● TIMP-1 only expressed in 1/20 patients
Neely et al. [21] 1997 MMP-9 + TIMP-1 ● MMP-9 expression in burn samples
● MMP-9 activity in burn vs unburned skin (20-30-fold; P<0.05)
● TIMP-1 mRNA expressed in burn and normal samples, with expression in burn wounds 
Schaffer et al. [31] 1997 MMP-9 + TIMP-1 ● MMP-9 present in dermis and epidermis 5-15 days post-injury
● TIMP-1 levels initially, as wound repair progresses
Stricklin et al. [32] 1994 TIMP-1 ● TIMP-1 detected throughout wound 6 days post-burn; not present in uninjured skin
Young & Grinnell [22] 1994 MMP-9 ● ProMMP-9 & MMP-9 complex observed in burn fluid on day 0
● Higher MMP-9 detected day 2, to a peak on day 4, then 
● Activated MMP-9 in non-epithelializing burn wounds and in epithelializing burn wounds
Stricklin et al. [23] 1993 TIMP-1 ● TIMP-1 highly expressed throughout wound but not in necrotic or nonwounded areas
● Weak TIMP-1 signals at day 2 and from 22-34 days post-injury
MMP-9 = matrix metalloproteinase-9; TIMP-1 = tissue inhibitor of metalloproteinase-1.
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within lung tissue, 3 hours after 30% TBSA burn 
injury [10].
MMP-9 expression in brain after severe full-
thickness burns (60-70% TBSA) in Sprague-
Dawley rats was described in three studies 
included in this systematic review [6, 29, 30] 
(Table 6). Brain MMP-9 mRNA was shown to be 
significantly increased at 3 and 7 hours after 
burn [6, 30], with a return to control levels by 
24 hours [30]. Increased MMP-9 protein and 
activity were first reported at 7 hours post-inju-
ry [29]. A review of forensic autopsy cases also 
reported significantly elevated MMP-9 mRNA in 
brains of severe burns patients who died >30 
minutes after injury [16].
Correlation between MMP-9 and TIMP-1 and 
burn injury severity
Of three cohort studies that assessed correla-
tions between circulating MMP-9 and burn inju-
ry severity, only Nagy et al. showed a weak posi-
tive correlation between MMP-9 and TBSA [5, 
12, 20] (Table 7). Reiss et al. reported a posi-
tive correlation between MMP-9 protein and 
activity in burned skin and burn depth [18]. No 
study found an association between MMP-9 
and survival or other outcome measures (Table 
7).
In direct contrast to MMP-9, circulating TIMP-1 
was associated with survival [5, 12], with 
Table 5. Systemic expression of MMP-9 and TIMP-1 following burn injury
Authors Year Parameter Major Findings
Nong et al. [15] 2016 MMP-9 + TIMP-1 ● MMP-9 and TIMP-1 upregulated vs non-burn controls (P<0.05)
Hastbacka et al. [12] 2015 MMP-9 + TIMP-1 ● MMP-9 early (P = 0.016 vs controls), to control values by 12-24 hours
● TIMP-1 vs controls (P<0.001) and higher in >20% vs <20% TBSA (P<0.002)
● TIMP-1 later than MMP-9 (12 hours) and remained high in >20% TBSA burn patients
Nagy et al. [5] 2015 MMP-9 + TIMP-1 ● MMP-9 elevated on admission (P<0.001) and thereafter 
● MMP-9 lower on days 4-6 vs non-burned controls (P<0.05)
● TIMP-1 at day 2 (P<0.001) and elevated to day 5
● MMP-9/TIMP-1 ratio lower on days 3-5 vs controls (P<0.01)
Stagg et al. [27] 2013 MMP-9 ● MMP-9 present in burn but not sham serum 3 hours after injury
● MMP-9 activity 3 hours after burn (P<0.01)
Ulrich et al. [17] 2010 MMP-9 + TIMP-1 ● No difference in serum MMP-9 in patients with extended hypertrophic scars vs controls
● TIMP-1 in patients with extended hypertrophic scars vs control patients (P<0.05)
Swann et al. [30] 2007 MMP-9 ● No difference in serum MMP-9 vs controls at 7 hours (P>0.05)
● MMP-9 activity at 7 hours (P<0.05), returning to control levels between 7 and 12 hours
Dasu et al. [19] 2003 MMP-9 + TIMP-1 ● MMP-9 levels at day 21 vs controls (P<0.05)
● TIMP-1 levels did not change with time after burn but were higher than controls from day 3 
to day 21 (P<0.05)
Ulrich et al. [20] 2003 MMP-9 + TIMP-1 ● MMP-9 between day 3 and day 14 vs non-burn controls (P<0.05)
● TIMP-1 at day 3 (P<0.05) and remained significantly elevated 6 months after injury
● TIMP-1 vs control group from day 1 to 6 months (P<0.05)
Young & Grinnell [22] 1994 MMP-9 ● Little gelatinase activity detected in plasma
MMP-9 = matrix metalloproteinase-9; TIMP-1 = tissue inhibitor of metalloproteinase-1; TBSA = total body surface area.
Table 6. Peripheral expression and activity of MMP-9 and TIMP-1 following burn injury
Authors Year Tissue Parameter Major Findings
Brightwell et al. [24] 2020 Skeletal muscle MMP-9 + TIMP-1 ● No change in MMP-9 after burn
● TIMP-1 at day 7 (P = 0.048) and day 14 (P = 0.0001)
Hernandez et al. [11] 2018 Tendon MMP-9 ● MMP-9 after injury (P<0.05 vs control at day 3)
● Second at day 14 (>20-fold vs control; P<0.05)
Wiggins-Dohlvik et al. [10] 2016 Lung tissue MMP-9 ● MMP-9 protein higher in burn animals vs shams (P = 0.15)
● MMP-9 activity ~40% in burn animals (P = 0.02)
Wang et al. [16] 2013 Brain MMP-9 ● MMP-9 in deaths due to severe burns (P<0.05)
Reyes et al. [29] 2009 Brain MMP-9 ● MMP-9 expression and activity 7 hours post-burn (P<0.01)
Berger et al. [6] 2007 Brain MMP-9 ● MMP-9 3 hours after thermal injury (P<0.05) and remained high at 
7 hours (P<0.05 vs unburned controls)
Swann et al. [30] 2007 Brain MMP-9 ● MMP-9 post-burn (P<0.01 at 3 hours and 7 hours), returning to 
control levels at 24 hours
MMP-9 = matrix metalloproteinase-9; TIMP-1 = tissue inhibitor of metalloproteinase-1.
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Hastbacka and colleagues showing plasma 
levels at 24 to 48 hours predicted 90 day sur-
vival when controlling for age and injury severity 
[12] (Table 7). Plasma TIMP-1 also correlated 
with Sequential Organ Failure Assessment 
(SOFA), as well as noradrenaline and fluid vol-
ume administered [12]. One study reported a 
correlation between serum TIMP-1 and TBSA 
on days 3 and 7 after burn [20], but no correla-
tion was found by Nagy et al. [5].
Discussion
MMP-9 and its endogenous inhibitor TIMP-1 
are key regulators of inflammation and wound 
healing, that are are significantly upregulated 
both locally and systemically in burns patients. 
Given their pivotal role in the acute inflamma-
tory response following burn injury, perturba-
tions in the dynamic balance of expression and 
activity of MMP-9 and TIMP-1 might also con-
tribute to secondary tissue damage and mortal-
ity. We conducted a systematic review of stud-
ies reporting local, systemic and peripheral 
MMP-9 and/or TIMP-1 expression after burn 
trauma and found a potential role for TIMP-1 as 
a prognostic blood biomarker. The main find-
ings will now be discussed.
Increased MMP-9 at the site of injury and 
systemically
Increased MMP-9 was reported at the site of 
injury in all studies early after burn trauma, con-
sistent with its known role in the early inflam-
matory phase of wound healing [3, 33] (Table 
4). However in excess, MMP-9 can delay wound 
healing, with excessive MMP-9 activity in non-
healing, non-epithelializing wounds a finding of 
two studies in this review [18, 22]. Critical to 
MMP-9 regulation is its endogenous inhibitor 
TIMP-1, whose expression is upregulated by 
fibroblasts ~2 to 3 days after burn, resulting in 
inactivation of MMP-9 and prevention of exces-
sive ECM degradation [3]. Reduced TIMP-1 pro-
duction has been associated with delayed 
wound healing in elderly patients [18], which is 
consistent with the higher levels of MMP-9 
reported in wounded old skin compared with 
wounded young skin in animal models [26]. 
Conversely, excessive local production of TIMP-
1 may increase collagen synthesis and deposi-
tion, leading to severe fibrosis, and pathologic 
scar formation as was found by Ulrich et al. 
[17]. Serum TIMP-1 was also significantly ele-
vated in burns patients with hypertrophic scar-
ring [17, 20], suggesting it may be a useful bio-
marker. Early identification of at-risk patients 
with elevated serum TIMP-1 may facilitate tar-
geted treatment to reduce hypertrophic scar-
ring, which requires multiple surgeries and 
causes significant disability.
Our analysis also found significant increases of 
MMP-9 in the circulation in multiple studies 
early after burn injury [5, 12, 15, 20, 27] (Table 
5). This is consistent with early increases in 
proinflammatory cytokines after burns which 
stimulate MMP-9 synthesis [5, 12]. However, 
there was one outlier. The study of Dasu et al. 
found no systemic MMP-9 increase until day 21 
Table 7. Correlation of MMP-9 and TIMP-1 with injury severity and outcomes
Authors Year Parameter Major Findings
Hastbacka et al. [12] 2015 MMP-9 + TIMP-1 ● MMP-9 at 24-48 hours did not correlate with TBSA or outcome
● Plasma TIMP-1 showed high positive correlation with TBSA
● TIMP-1 correlated with SOFA (r = 0.592, P = 0.002), fluid (r = 0.63, P<0.001) and noradrena-
line (r = 0.753, P<0.001)
● TIMP-1 independently associated with mortality (P = 0.03)
● TIMP-1 at 24-48 hours predicted 90-day survival (AUC 0.846 [95% CI 0.603-0.989]; P = 
0.002)
Nagy et al. [5] 2015 MMP-9 + TIMP-1 ● Admission plasma MMP-9 showed weak correlation with burn extent (r = 0.437; P = 0.014) 
but no association with survival
● Plasma TIMP-1 did not correlate with extent of burns, but showed weak significant correlation 
with survival (Day 5: r = 0.432, P = 0.028; Day 6: r = 0.444, P = 0.014) 
Reiss et al. [18] 2009 MMP-9 + TIMP-1 ● Expression and activation of MMP-9 in injured tissue correlated with degree of injury and 
location relative to wound
Ulrich et al. [20] 2003 MMP-9 + TIMP-1 ● No correlation between serum MMP-9 and TBSA
● Serum TIMP-1 on day 3 and day 7 correlated with TBSA (r = 0.46 and r = 0.53, respectively; 
P<0.05)
● Serum TIMP-1 at 6 months correlated with Burn Scar Index (r = 0.65, P<0.05)
MMP-9 = matrix metalloproteinase-9; TIMP-1 = tissue inhibitor of metalloproteinase-1; TBSA = total body surface area; SOFA = Sequential Organ Failure Assessment; 
AUC = area under the curve; CI = confidence interval. The Burn Scar index, often called the Vancouver Scar Scale, scores burn scars on four parameters: (1) pigmenta-
tion, (2) vascularity, (3) pliability, and (4) height.
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after burn [19]. This may be an age-associated 
effect since this study included only pediatric 
patients (7.9 2.5 years) (Table 1) [19]. Differ- 
ences may also be related to the extent and 
severity of burns. For example, earlier and high-
er levels of circulating MMP-9 were reported in 
the studies of Hastbacka et al. [12] and Nagy et 
al. [34] compared with Ulrich et al. [20], which 
are likely related to the severity of injury with 
TBSA >20%, 15-80%, and >5% for the three 
studies, respectively (Table 1). There is a posi-
tive correlation between the degree of the 
burn-induced inflammatory response and [35, 
36], resulting in increased cytokine release in 
more severely injured patients, and therefore 
increased MMP-9. TIMP-1 synthesis is also 
stimulated by inflammatory cytokines [12], with 
multiple studies reviewed reporting elevated 
serum or plasma TIMP-1 after injury, and higher 
levels in more severely injured patients (Table 
5) [5, 12, 19, 20]. Age-associated differences 
in MMP-9 and TIMP-1, as well as differences 
related to burn severity, may be important vari-
ables following burn trauma and need further 
investigation.
MMP-9/TIMP-1 influences inflammation and 
injury at distant sites
The present analysis found evidence of the 
MMP-9/TIMP-1 system contributing to inflam-
mation and tissue injury distant from the burn 
site (Table 6). An example is burn-associated 
musculoskeletal damage including collagen 
breakdown in skeletal muscle and tendon 
remodeling [11, 24]. Two organs of importance 
are the lungs, the site of the most prevalent 
organ dysfunction after severe burns [37], and 
brain, given burn encephalopathy is highly cor-
related with mortality [29]. In the lungs, MMP-9 
secreted by activated polymorphonuclear 
(PMN) leukocytes may be involved in mediating 
acute lung injury (ALI), which is also associated 
with mortality [13, 28]. Wiggins-Dohlvik et al. 
reported a non-significant elevation in MMP-9 
protein in lung, but a significant 40% increase 
in activity [10]. In contrast to the soluble form, 
MMP-9 bound to PMN surfaces is resistant to 
TIMP-1 inhibition [13], such that the increased 
activity may be due to reduced inhibition rather 
than increased synthesis [10]. Furthermore, 
TIMP-1 may also be localized on the surface of 
activated PMNs, where it plays an opposite role 
by anchoring soluble MMP-9, and thereby pro-
moting MMP-9 proteolytic activity rather than 
inhibiting it [38]. MMP-9 synthesis and regula-
tion may therefore be tissue-specific, with fur-
ther investigation regarding the modulation of 
the MMP-9-TIMP-1 system in different tissue 
types required to develop targeted treatments.
MMP-9 increases in the brain after burn injury
MMPs are critical for maintaining integrity of 
the blood-brain barrier (BBB) as well as neuro-
nal network remodeling [1, 6]. All studies exam-
ining MMP-9 expression and activity in the 
brain showed significant increases following 
burn injury [6, 16, 29, 30], consistent with find-
ings following other traumatic stimuli such as 
brain injury and stroke [39]. This increase may 
result from (i) neuronal expression in response 
to upregulated cytokines such as TNF-α and 
IL-1β in the brain early after peripheral burn 
injury [29, 30], or (ii) as a result of leukocyte 
infiltration, if the BBB is compromised [39]. 
MMP-9 itself digests the endothelial basal lam-
ina of the BBB, leading to increased permeabil-
ity and burn-associated cerebral edema [16, 
29, 39]. Increased brain MMP-9 is unlikely to 
be caused by systemic expression given that in 
the study of Swann and colleagues, brain 
expression increased by 3 hours after injury, 
while serum MMP-9 levels did not [30]. Further 
understanding of the underlying mechanisms 
of MMP-9 synthesis and regulation in the brain 
after burns is vital for the development of ther-
apeutic interventions to reduce or correct BBB 
dysfunction and cerebral complications that 
are highly correlated with mortality [6, 16, 29].
TIMP-1 as a prognostic marker of burn severity 
and outcome
Changes in plasma levels of MMP-9 and TIMP-1 
are increasingly being evaluated as prognostic 
biomarkers in critically ill patients. While lower 
levels of circulating MMP-9 have been associ-
ated with improved outcomes including sur- 
vival in sepsis [12], this review found no evi-
dence of a correlation between serum or plas-
ma MMP-9 and extent of burn injury or outcome 
measures (Table 7) [5, 12, 20]. Circulating 
TIMP-1, on the other hand, showed good corre-
lation with TBSA [12, 20], survival [5, 12], and 
other surrogate markers of burn injury severity 
and outcome [12, 20], and may be a promising 
biomarker in outcome prognostication of burns 
patients.
MMP-9 and TIMP-1 in burn injury
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Limitations
These conclusions are limited by the heteroge-
neity of the reviewed studies which included 
burns covering 1 to 80% TBSA and a mix of 
superficial, partial and full-thickness burns 
(Table 1). In addition, the studies were all 
monocentric and ~40% had sample sizes less 
than 20 subjects, including Young and Grinnell 
which reported on only three patients [22]. 
Comparisons are also limited by the range of 
sampling times and time between measure-
ments, which has a strong influence on results 
as shown by the temporal changes in expres-
sion reported in different studies (Tables 3-5). 
Furthermore, burns injury is often complicated 
by sepsis, which has also been shown to upreg-
ulate MMPs [40]. It was not possible to assess 
the contribution of sepsis as a confounding 
variable since Hastbacka et al. was the only 
study to report suspected or verified sepsis in 
their patient cohort [12].
Another important consideration when evaluat-
ing these findings is the detection method used 
to quantitate levels of MMP-9 and TIMP-1. 
Measurement is complicated by the fact that 
MMPs exist in three forms, as inactive pro-
MMPs, active MMPs, and TIMP-complexed 
MMPs [8]. As shown in Table 3, different stud-
ies included in this systematic review employed 
different detection methods all of which have 
their own limitations. Seven studies reported 
gene expression only [6, 15, 16, 23, 30-32], 
and while there is normally reasonable correla-
tion between mRNA and protein levels [41], 
mRNA cannot measure the activity of protein-
ases. Similarly the use of Western blotting, 
immunohistochemistry, or ELISAs to detect 
MMP-9 protein in circulation or tissue does not 
reflect its biological activity. The antibodies 
used in these assays may immunoreact with 
pro-MMP-9, active MMP-9, and TIMP-com- 
plexed MMP-9, as well as other degradation 
products [4, 8]. Gelatin substrate zymography 
analysis which is the most common technique 
to measure gelatinase activity, and was report-
ed in four studies [18, 21, 22, 27], also detects 
some inactive MMP proforms reducing its sen-
sitivity and reliability [8].
Future research
The results of this systematic review suggest a 
promising role for TIMP-1 as a prognostic mark-
er in burns patients. Large-scale multi-center 
prospective cohort studies, in both pediatric 
and adult patients, including equal male-female 
representation, with repeated sampling of 
blood and burn wounds from the time of injury 
until 6 to 12 months, would help validate the 
reliability of TIMP-1 as a prognostic outcome 
marker. In addition, the following knowledge 
gaps require further research: (1) Circulating 
MMP-9 and MMP-9: TIMP-1 ratio as predictors 
of morbidity including delayed wound healing in 
burns patients. A blood-based biomarker would 
be beneficial for risk stratification and person-
alized treatment. (2) Age-specific pathophysio-
logical differences in MMP-9 and TIMP-1 
expression following burn injury. Impaired 
wound healing in aged burn patients remains a 
therapeutic challenge [42] that will continue to 
grow with an aging population. Improved under-
standing of MMP-9/TIMP-1 system perturba-
tions in age-associated wound healing differ-
ences may identify novel therapeutic strategies. 
This review also revealed a potential difference 
in the MMP-9 systemic response between pedi-
atric and adult patients which requires further 
investigation. (3) Sex-specific pathophysiologi-
cal differences in tissue and circulating MMP-9 
and TIMP-1 expression following burn injury. 
Female patients have worse outcomes follow-
ing burn injury compared to their male counter-
parts, though the mechanisms underlying this 
discrepancy are currently unknown [43]. No 
study has assessed sex differences in MMP-9/
TIMP-1 expression following burn injury, with all 
preclinical studies using only male animals, 
and males also comprising the majority of the 
clinical patient cohorts (Table 1). Future pre-
clinical studies should include and separately 
analyze male and female animals, with greater 
female representation also required in clinical 
studies. (4) Correlation between circulating 
MMP-9 and TIMP-1 and early development of 
acute lung injury and cerebral complications in 
burns patients to optimize delivery of care and 
improve outcomes.
Conclusion
TIMP-1 may be a useful serum biomarker in 
major burns patients. Further evaluation of the 
MMP-9-TIMP-1 system might aid in the develop-
ment of improved prognostic guidelines and 
targeted therapeutic strategies for wound heal-
ing, as well as correction of hyperpermeability 
MMP-9 and TIMP-1 in burn injury
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in the lungs and brain following major burn 
injury.
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